Monopar Therapeutics Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Monopar Therapeutics Inc. (MNPR) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-12
- Monopar Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.56M, a 2284.06% increase year-over-year.
- Monopar Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$287.14K.
- Monopar Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $738.68K, a 34.92% decline year-over-year.
- Monopar Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $355.10K, a 1137.63% increase year-over-year.
- Monopar Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $388.22K, a 23.40% decline from fiscal 2024.
- Monopar Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $506.79K.
- Monopar Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$1.33M, a 190.21% decline from fiscal 2022.
- Monopar Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $1.48M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.27M 10-Q · filed 2026-08-12 | $2.01M derived: sum of 3 quarters · filed 2026-08-12 | $2.37M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$287.14K 10-Q · filed 2026-05-14 | $451.54K derived: sum of 2 quarters · filed 2026-05-14 | $806.64K derived: sum of 3 quarters · filed 2026-05-14 | $872.05K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $738.68K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.09M derived: sum of 2 quarters · filed 2026-03-27 | $1.16M derived: sum of 3 quarters · filed 2026-08-12 | $388.22K 10-K · filed 2026-03-27 |
| 2025-09-30 | $355.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $420.50K derived: sum of 2 quarters · filed 2026-08-12 | -$350.46K 10-Q · filed 2025-11-13 | $784.62K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $65.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$705.57K 10-Q · filed 2026-08-12 | $429.52K derived: sum of 3 quarters · filed 2026-08-12 | $458.21K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$770.97K 10-Q · filed 2026-05-14 | $364.12K derived: sum of 2 quarters · filed 2026-05-14 | $392.81K derived: sum of 3 quarters · filed 2026-05-14 | $47.06K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.16M derived: sum of 2 quarters · filed 2026-03-27 | $818.03K derived: sum of 3 quarters · filed 2026-03-27 | $506.79K 10-K · filed 2026-03-27 |
| 2024-09-30 | $28.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$317.06K derived: sum of 2 quarters · filed 2025-11-13 | -$628.30K 10-Q · filed 2025-11-13 | -$841.30K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$345.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$656.99K 10-Q · filed 2025-08-12 | -$869.99K derived: sum of 3 quarters · filed 2025-08-12 | -$1.37M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$311.24K 10-Q · filed 2025-05-13 | -$524.24K derived: sum of 2 quarters · filed 2025-05-13 | -$1.02M derived: sum of 3 quarters · filed 2025-05-13 | -$1.39M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$213.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$709.89K derived: sum of 2 quarters · filed 2025-03-31 | -$1.08M derived: sum of 3 quarters · filed 2025-03-31 | -$1.33M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$496.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$868.61K derived: sum of 2 quarters · filed 2024-11-08 | -$1.12M 10-Q · filed 2024-11-08 | $75.33K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$371.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$623.65K 10-Q · filed 2024-08-09 | $572.22K derived: sum of 3 quarters · filed 2024-08-09 | $294.69K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$251.92K 10-Q · filed 2024-05-09 | $943.94K derived: sum of 2 quarters · filed 2024-05-09 | $666.42K derived: sum of 3 quarters · filed 2024-05-09 | $1.76M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $918.34K derived: sum of 2 quarters · filed 2024-03-28 | $2.01M derived: sum of 3 quarters · filed 2024-03-28 | $1.48M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$277.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $814.76K derived: sum of 2 quarters · filed 2023-11-09 | $282.44K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $559.96K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$532.32K 10-Q · filed 2023-05-11 | |||
| 2021-09-30 | $136.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $433.75K derived: sum of 2 quarters · filed 2022-11-10 | $63.36K 10-Q · filed 2022-11-10 | $700.33K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $297.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$72.94K 10-Q · filed 2022-08-11 | $564.03K derived: sum of 3 quarters · filed 2022-08-11 | $542.61K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$370.39K 10-Q · filed 2022-05-12 | $266.58K derived: sum of 2 quarters · filed 2022-05-12 | $245.16K derived: sum of 3 quarters · filed 2022-05-12 | $408.31K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $636.97K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $615.55K derived: sum of 2 quarters · filed 2021-11-12 | $778.70K derived: sum of 3 quarters · filed 2021-11-12 | $447.60K 10-K · filed 2021-03-25 |
| 2020-09-30 | -$21.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $141.73K derived: sum of 2 quarters · filed 2021-11-12 | -$189.37K 10-Q · filed 2021-11-12 | $114.86K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $163.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$167.95K 10-Q · filed 2021-08-12 | $136.28K derived: sum of 3 quarters · filed 2021-08-12 | $6.86K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$331.11K 10-Q · filed 2021-05-13 | -$26.88K derived: sum of 2 quarters · filed 2021-05-13 | -$156.29K derived: sum of 3 quarters · filed 2021-05-13 | -$255.42K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $304.23K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $174.81K derived: sum of 2 quarters · filed 2021-03-25 | $75.68K derived: sum of 3 quarters · filed 2021-03-25 | $243.53K 10-K · filed 2021-03-25 |
| 2019-09-30 | -$129.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$228.55K derived: sum of 2 quarters · filed 2020-11-12 | -$60.70K 10-Q · filed 2020-11-12 | $26.96K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$99.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $68.72K 10-Q · filed 2020-08-06 | $156.38K derived: sum of 3 quarters · filed 2020-08-06 | $145.13K derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $167.85K 10-Q · filed 2020-05-07 | $255.51K derived: sum of 2 quarters · filed 2020-05-07 | $244.26K derived: sum of 3 quarters · filed 2020-05-07 | $276.81K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $87.66K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $76.41K derived: sum of 2 quarters · filed 2020-03-27 | $108.95K derived: sum of 3 quarters · filed 2020-03-27 | $87.68K 10-K · filed 2020-03-27 |
| 2018-09-30 | -$11.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $21.30K derived: sum of 2 quarters · filed 2019-11-12 | $26.00 10-Q · filed 2019-11-12 | -$26.04K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $32.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $11.27K 10-Q · filed 2019-08-08 | -$14.80K derived: sum of 3 quarters · filed 2019-08-08 | $120.05K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | -$21.27K 10-Q · filed 2019-05-10 | -$47.34K derived: sum of 2 quarters · filed 2019-05-10 | $87.51K derived: sum of 3 quarters · filed 2019-05-10 | $172.23K derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | -$26.07K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $108.78K derived: sum of 2 quarters · filed 2019-02-26 | $193.50K derived: sum of 3 quarters · filed 2019-02-26 | $247.36K 10-K · filed 2019-02-26 |
| 2017-09-30 | $134.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $219.57K derived: sum of 2 quarters · filed 2018-11-09 | $273.43K 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $84.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $138.58K 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $53.86K 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | -$9.33K 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |